Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Review Article

Herbal Medicines as Adjuvants for the Treatment of Chemotherapy-Induced Diarrhea

Author(s): Zicong Zheng, Songpol Srinual, Jie Chen, Li Li, Ting Du, Ming Hu, Rongjin Sun* and Song Gao*

Volume 24, Issue 6, 2023

Published on: 31 August, 2023

Page: [422 - 433] Pages: 12

DOI: 10.2174/1389200224666230817102224

Price: $65

Abstract

Background: Chemotherapeutic drugs used in cancer treatment often result in gastrointestinal toxicity, notably diarrhea, impacting patients’ quality of life. Complementary and Alternative Medicine (CAM) has garnered increasing interest as an alternative to conventional approaches as a potential solution for managing chemotherapyinduced diarrhea (CID).

Objective: To summarize current research focusing on herbal medicines as adjuvant therapy to prevent or treat chemotherapy-induced diarrhea, including clinical assessments, mechanism of actions, active components, and potential pharmacokinetic interactions between herbal medicines and chemotherapeutic drugs.

Methods: We performed the literature review from PubMed, CNKI, Google Scholar, Web of Science, and Scopus using “Chemotherapy”, “Diarrhea,” and “Complementary and Alternative Medicine” as the search keywords.

Results: Using herbal medicines as adjuvants provides an effective approach to treating or preventing CID with improved or unaffected antitumor activity of chemotherapeutic drugs. Among these herbal formulations, scutellaria, ginger, and ginseng are the most frequently used herbs in the prescriptions for CID. The main antidiarrheal components in herbs include wogonin, baicalin, chrysin, quercetin, gingerol, and ginsenosides. These herbs, formulations, and bioactive components relieved CID through different mechanisms, including directly decreasing local drug exposure, anti-inflammation, inhibiting epithelial apoptosis, or promoting epithelium stem cell regeneration. The application of herbal medicines as adjunctive therapies showed efficacy in preventing or treating CID in multiple clinical trials. However, more well-designed clinical studies are expected to validate the results further. Despite some clinical studies demonstrating that certain herbal medicines could potentially attenuate CID and improve efficacy, it remains necessary to evaluate herbal safety. The interactions between herbs and drugs are also potential concerns, but few clinical trials have focused on investigating this aspect.

Conclusion: In clinical practise, herbal medications show potential as adjuvant treatments for gastrointestinal toxicities induced by chemotherapy, particularly diarrhoea. Further well-designed clinical studies are needed to validate their efficacy, ensure safety, and explore potential drug-herb interactions.

Keywords: Chemotherapy-induced diarrhea, herb medicine, side effects, toxicity, clinical trials, Review.

Graphical Abstract
[1]
National cancer institute common terminology criteria for adverse events (CTCAE) v4.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
[2]
Swami, U.; Goel, S.; Mani, S. Therapeutic targeting of CPT-11 induced diarrhea: A case for prophylaxis. Curr. Drug Targets, 2013, 14(7), 777-797.
[http://dx.doi.org/10.2174/1389450111314070007] [PMID: 23597015]
[3]
Hoff, P.M.; Saragiotto, D.F.; Barrios, C.H.; del Giglio, A.; Coutinho, A.K.; Andrade, A.C.; Dutra, C.; Forones, N.M.; Correa, M.; Portella, M.S.O.; Passos, V.Q.; Chinen, R.N.; van Eyll, B. Randomized phase III trial exploring the use of long-acting release octreotide in the pre-vention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial. J. Clin. Oncol., 2014, 32(10), 1006-1011.
[http://dx.doi.org/10.1200/JCO.2013.50.8077] [PMID: 24516038]
[4]
Xu, W.; Towers, A.D.; Li, P.; Collet, J.P. Traditional chinese medicine in cancer care: Perspectives and experiences of patients and profes-sionals in China. Eur. J. Cancer Care, 2006, 15(4), 397-403.
[http://dx.doi.org/10.1111/j.1365-2354.2006.00685.x] [PMID: 16968323]
[5]
Dy, G.K.; Bekele, L.; Hanson, L.J.; Furth, A.; Mandrekar, S.; Sloan, J.A.; Adjei, A.A. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J. Clin. Oncol., 2004, 22(23), 4810-4815.
[http://dx.doi.org/10.1200/JCO.2004.03.121] [PMID: 15570083]
[6]
Okumi, H.; Koyama, A. Kampo medicine for palliative care in Japan. Biopsychosoc. Med., 2014, 8(1), 6.
[http://dx.doi.org/10.1186/1751-0759-8-6] [PMID: 24447861]
[7]
Qi, F.; Zhao, L.; Zhou, A.; Zhang, B.; Li, A.; Wang, Z.; Han, J. The advantages of using traditional Chinese medicine as an adjunctive ther-apy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci. Trends, 2015, 9(1), 16-34.
[http://dx.doi.org/10.5582/bst.2015.01019] [PMID: 25787906]
[8]
Guo, Y.; Shi, M.; Shen, X.; Yang, C.; Yang, L.; Zhang, J. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treat-ment of colorectal cancer: A meta-analysis. Clin. Colorectal Cancer, 2014, 13(2), 110-118.
[http://dx.doi.org/10.1016/j.clcc.2013.12.004] [PMID: 24461997]
[9]
Rothenberg, M.L.; Meropol, N.J.; Poplin, E.A.; Van Cutsem, E.; Wadler, S. Mortality associated with irinotecan plus bolus fluoroura-cil/leucovorin: Summary findings of an independent panel. J. Clin. Oncol., 2001, 19(18), 3801-3807.
[http://dx.doi.org/10.1200/JCO.2001.19.18.3801] [PMID: 11559717]
[10]
Benson, A.B., III; Ajani, J.A.; Catalano, R.B.; Engelking, C.; Kornblau, S.M.; Martenson, J.A., Jr; McCallum, R.; Mitchell, E.P.; O’Dorisio, T.M.; Vokes, E.E.; Wadler, S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol., 2004, 22(14), 2918-2926.
[http://dx.doi.org/10.1200/JCO.2004.04.132] [PMID: 15254061]
[11]
United states food and drug administration FDA drug safety communication.FDA Drug Safety Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-heart-problems-high-doses-antidiarrheal accessed on January 15
[12]
Blum, J.L.; Jones, S.E.; Buzdar, A.U.; LoRusso, P.M.; Kuter, I.; Vogel, C.; Osterwalder, B.; Burger, H.U.; Brown, C.S.; Griffin, T. Multi-center phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol., 1999, 17(2), 485-493.
[http://dx.doi.org/10.1200/JCO.1999.17.2.485] [PMID: 10080589]
[13]
Cassidy, J.; Twelves, C.; Van Cutsem, E.; Hoff, P.; Bajetta, E.; Boyer, M.; Bugat, R.; Burger, U.; Garin, A.; Graeven, U.; McKendrick, J.; Maroun, J.; Marshall, J.; Osterwalder, B.; Pérez-Manga, G.; Rosso, R.; Rougier, P.; Schilsky, R.L. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous5-fluorouracil/leucovorin. Ann. Oncol., 2002, 13(4), 566-575.
[http://dx.doi.org/10.1093/annonc/mdf089] [PMID: 12056707]
[14]
O’Shaughnessy, J.A.; Blum, J.; Moiseyenko, V.; Jones, S.E.; Miles, D.; Bell, D.; Rosso, R.; Mauriac, L.; Osterwalder, B.; Burger, H.U.; Laws, S. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophospha-mide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann. Oncol., 2001, 12(9), 1247-1254.
[http://dx.doi.org/10.1023/A:1012281104865] [PMID: 11697835]
[15]
Wagstaff, A.J.; Ibbotson, T.; Goa, K.L. Capecitabine. Drugs, 2003, 63(2), 217-236.
[http://dx.doi.org/10.2165/00003495-200363020-00009] [PMID: 12515569]
[16]
Rougier, P.; Van Cutsem, E.; Bajetta, E.; Niederle, N.; Possinger, K.; Labianca, R.; Navarro, M.; Morant, R.; Bleiberg, H.; Wils, J.; Awad, L.; Herait, P.; Jacques, C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 1998, 352(9138), 1407-1412.
[http://dx.doi.org/10.1016/S0140-6736(98)03085-2] [PMID: 9807986]
[17]
Douillard, J.Y.; Cunningham, D.; Roth, A.D.; Navarro, M.; James, R.D.; Karasek, P.; Jandik, P.; Iveson, T.; Carmichael, J.; Alakl, M.; Gru-ia, G.; Awad, L.; Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet, 2000, 355(9209), 1041-1047.
[http://dx.doi.org/10.1016/S0140-6736(00)02034-1] [PMID: 10744089]
[18]
Saltz, L.B.; Douillard, J.Y.; Pirotta, N.; Alakl, M.; Gruia, G.; Awad, L.; Elfring, G.L.; Locker, P.K.; Miller, L.L. Irinotecan plus fluoroura-cil/leucovorin for metastatic colorectal cancer: A new survival standard. Oncologist, 2001, 6(1), 81-91.
[http://dx.doi.org/10.1634/theoncologist.6-1-81] [PMID: 11161231]
[19]
Leichman, C.G.; Fleming, T.R.; Muggia, F.M.; Tangen, C.M.; Ardalan, B.; Doroshow, J.H.; Meyers, F.J.; Holcombe, R.F.; Weiss, G.R.; Mangalik, A. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J. Clin. Oncol., 1995, 13(6), 1303-1311.
[http://dx.doi.org/10.1200/JCO.1995.13.6.1303] [PMID: 7751875]
[20]
Salliot, C.; van der Heijde, D. Long-term safety of methotrexate monotherapy in patients with Rheumatoid arthritis: A systematic literature research. Ann. Rheum. Dis., 2009, 68(7), 1100-1104.
[http://dx.doi.org/10.1136/ard.2008.093690] [PMID: 19060002]
[21]
Boussios, S.; Pentheroudakis, G.; Katsanos, K.; Pavlidis, N. Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management. Ann. Gastroenterol., 2012, 25(2), 106-118.
[PMID: 24713845]
[22]
Hanna, N.; Shepherd, F.A.; Fossella, F.V.; Pereira, J.R.; De Marinis, F.; von Pawel, J.; Gatzemeier, U.; Tsao, T.C.Y.; Pless, M.; Muller, T.; Lim, H.L.; Desch, C.; Szondy, K.; Gervais, R. Shaharyar; Manegold, C.; Paul, S.; Paoletti, P.; Einhorn, L.; Bunn, P.A., Jr Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol., 2004, 22(9), 1589-1597.
[http://dx.doi.org/10.1200/JCO.2004.08.163] [PMID: 15117980]
[23]
Dong, L.; Han, Z.; Feng, Z.; Jia, Z. Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors. J. Int. Med. Res., 2014, 42(1), 191-197.
[http://dx.doi.org/10.1177/0300060513505808] [PMID: 24398758]
[24]
Karayama, M.; Inui, N.; Kuroishi, S.; Yokomura, K.; Toyoshima, M.; Shirai, T.; Masuda, M.; Yamada, T.; Yasuda, K.; Suda, T.; Chida, K. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: A randomized, phase II study. Cancer Chemother. Pharmacol., 2013, 72(2), 445-452.
[http://dx.doi.org/10.1007/s00280-013-2218-6] [PMID: 23807323]
[25]
Sun, Y.; Wu, Y.L.; Zhou, C.C.; Zhang, L.; Zhang, L.; Liu, X.Y.; Yu, S.Y.; Jiang, G.L.; Li, K.; Qin, S.K.; Ma, S.L.; Han, L.; Quinlivan, M.; Orlando, M.; Zhang, X.Q. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study. Lung Cancer, 2013, 79(2), 143-150.
[http://dx.doi.org/10.1016/j.lungcan.2012.10.015] [PMID: 23182660]
[26]
Cunningham, D.; Zalcberg, J.; Maroun, J.; James, R.; Clarke, S.; Maughan, T.S.; Vincent, M.; Schulz, J.; González Barón, M.; Facchini, T. Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer. Eur. J. Cancer, 2002, 38(4), 478-486.
[http://dx.doi.org/10.1016/S0959-8049(01)00413-0] [PMID: 11872339]
[27]
Zalcberg, J. Overview of the tolerability of?? Tomudex?? (raltitrexed): Collective clinical experience in advanced colorectal cancer. Anticancer Drugs, 1997, 8(Suppl. 2), S17-S22.
[http://dx.doi.org/10.1097/00001813-199708002-00004] [PMID: 9376633]
[28]
Zalcberg, J.R.; Cunningham, D.; Van Cutsem, E.; Francois, E.; Schornagel, J.; Adenis, A.; Green, M.; Iveson, A.; Azab, M.; Seymour, I. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Oncol., 1996, 14(3), 716-721.
[http://dx.doi.org/10.1200/JCO.1996.14.3.716] [PMID: 8622016]
[29]
Low, M.; Lee, D.; Coutsouvelis, J.; Patil, S.; Opat, S.; Walker, P.; Schwarer, A.; Salem, H.; Avery, S.; Spencer, A.; Wei, A. High-dose cy-tarabine (24 g/m 2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Intern. Med. J., 2013, 43(3), 294-297.
[http://dx.doi.org/10.1111/j.1445-5994.2012.02868.x] [PMID: 22757980]
[30]
Camera, A.; Andretta, C.; Villa, M.R.; Volpicelli, M.; Picardi, M.; Rossi, M.; Rinaldi, C.R.; Cioppa, P.D.; Ciancia, R.; Selleri, C.; Rotoli, B. Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. Hematol. J., 2003, 4(5), 346-350.
[http://dx.doi.org/10.1038/sj.thj.6200304] [PMID: 14502260]
[31]
Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishi-waki, Y.; Ohe, Y.; Yang, J.J.; Chewaskulyong, B.; Jiang, H.; Duffield, E.L.; Watkins, C.L.; Armour, A.A.; Fukuoka, M. Gefitinib or car-boplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 2009, 361(10), 947-957.
[http://dx.doi.org/10.1056/NEJMoa0810699] [PMID: 19692680]
[32]
Sato, A. Introduction of oxaliplatin for treating unresectable advanced or recurrent gastric cancer in clinical practice. Gan To Kagaku Ryoho, 2015, 42(4), 443-446.
[PMID: 25963690]
[33]
Misset, J.L. Oxaliplatin in practice. Br. J. Cancer, 1998, 77(Suppl. 4), 4-7.
[http://dx.doi.org/10.1038/bjc.1998.428] [PMID: 9647612]
[34]
van Gils, C.W.M.; de Groot, S.; Redekop, W.K.; Koopman, M.; Punt, C.J.A.; Uyl-de Groot, C.A. Real-world cost-effectiveness of oxali-platin in stage III colon cancer: A synthesis of clinical trial and daily practice evidence. PharmacoEconomics, 2013, 31(8), 703-718.
[http://dx.doi.org/10.1007/s40273-013-0061-6] [PMID: 23657918]
[35]
Liu, Q.G.; Zhao, X.; Xu, N.; Wu, L.H.; Li, S.Z.; Mi, Y.C. Organ toxicity and efficacy of high dose daunorubicin based chemotherapy in the treatment of acute leukemia. Zhonghua Xue Ye Xue Za Zhi, 2013, 34(7), 587-590.
[http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2013.07.006] [PMID: 23906451]
[36]
Hołowiecki, J.; Grosicki, S.; Kyrcz-Krzemien, S.; Skotnicki, A.B.; Piatkowska-Jakubas, B.; Warzocha, K.; Seferynska, I.; Zdziarska, B. Daunorubicin, cytarabine and fludarabine (daf) for remission induction in relapsed or refractory acute myeloid leukemia. evaluation of safety, tolerance and early outcome—polish adult leukemia group (PALG) pilot study. Ann. Hematol., 2008, 87(5), 361-367.
[http://dx.doi.org/10.1007/s00277-007-0421-4] [PMID: 18074133]
[37]
Bleiberg, H.; Cvitkovic, E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The european per-spective. Eur. J. Cancer, 1996, 32(Suppl. 3), S18-S23.
[http://dx.doi.org/10.1016/0959-8049(96)00293-6] [PMID: 8943661]
[38]
Gibson, R.J.; Keefe, D.M.K. Cancer chemotherapy-induced diarrhoea and constipation: Mechanisms of damage and prevention strategies. Support. Care Cancer, 2006, 14(9), 890-900.
[http://dx.doi.org/10.1007/s00520-006-0040-y] [PMID: 16604351]
[39]
O’Brien, M.E.R.; Ciuleanu, T.E.; Tsekov, H.; Shparyk, Y.; Čučeviá, B.; Juhasz, G.; Thatcher, N.; Ross, G.A.; Dane, G.C.; Crofts, T. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J. Clin. Oncol., 2006, 24(34), 5441-5447.
[http://dx.doi.org/10.1200/JCO.2006.06.5821] [PMID: 17135646]
[40]
Bryce, A.H.; Mattar, B.; Hillman, S.L.; Adjei, A.A.; Kugler, J.W.; Rowland, K., Jr; Wender, D.B.; Soori, G.; Perez, E.A.; Jett, J.R. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A north central cancer treatment group study. Am. J. Clin. Oncol., 2010, 33(4), 353-357.
[http://dx.doi.org/10.1097/COC.0b013e3181b0c27f] [PMID: 19935387]
[41]
Weroha, S.J.; Oberg, A.L.; Ziegler, K.L.A.; Dakhilm, S.R.; Rowland, K.M.; Hartmann, L.C.; Moore, D.F., Jr; Keeney, G.L.; Peethambaram, P.P.; Haluska, P. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peri-toneal carcinoma. Gynecol. Oncol., 2011, 122(1), 116-120.
[http://dx.doi.org/10.1016/j.ygyno.2011.03.030] [PMID: 21514634]
[42]
von Gruenigen, V.E.; Frasure, H.E.; Smith, D.A.; Fusco, N.L.; Eaton, S.M.; DeBernardo, R.L.; Heugel, A.M.; Waggoner, S.E. Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies. Anticancer Drugs, 2012, 23(7), 724-730.
[http://dx.doi.org/10.1097/CAD.0b013e32835396d4] [PMID: 22555194]
[43]
Jiang, J.; Huang, L.; Liang, X.; Zhou, X.; Huang, R.; Chu, Z.; Zhan, Q. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Acta Oncol., 2011, 50(4), 582-588.
[http://dx.doi.org/10.3109/0284186X.2010.546368] [PMID: 21190510]
[44]
Dunder, I.; Berker, B.; Atabekoglu, C.; Bilgin, T. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. Eur. J. Gynaecol. Oncol., 2005, 26(1), 79-82.
[PMID: 15755007]
[45]
Roth, B.J. Preliminary experience with paclitaxel in advanced bladder cancer. Semin. Oncol., 1995, 22(3)(Suppl. 6), 1-5.
[PMID: 7541150]
[46]
Smith, R.E.; Brown, A.M.; Mamounas, E.P.; Anderson, S.J.; Lembersky, B.C.; Atkins, J.H.; Shibata, H.R.; Baez, L.; DeFusco, P.A.; Davila, E.; Tipping, S.J.; Bearden, J.D.; Thirlwell, M.P. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National surgical adjuvant breast and bowel project protocol B-26. J. Clin. Oncol., 1999, 17(11), 3403-3411.
[http://dx.doi.org/10.1200/JCO.1999.17.11.3403] [PMID: 10550134]
[47]
Farrell, M.P.; Kummar, S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin. Colorectal Cancer, 2003, 2(4), 253-256.
[http://dx.doi.org/10.3816/CCC.2003.n.007] [PMID: 12620148]
[48]
Lam, W.; Jiang, Z.; Guan, F.; Huang, X.; Hu, R.; Wang, J.; Bussom, S.; Liu, S.H.; Zhao, H.; Yen, Y.; Cheng, Y.C. PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvi-ronment. Sci. Rep., 2015, 5(1), 9384.
[http://dx.doi.org/10.1038/srep09384] [PMID: 25819872]
[49]
Liu, S.H.; Cheng, Y.C. Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy. J. Ethnopharmacol., 2012, 140(3), 614-623.
[http://dx.doi.org/10.1016/j.jep.2012.01.047] [PMID: 22326673]
[50]
Xu, D.D.; Hou, X.Y.; Wang, O.; Wang, D.; Li, D.T.; Qin, S.Y.; Lv, B.; Dai, X.M.; Zhang, Z.J.; Wan, J.B.; Xu, F.G. A four-component com-bination derived from huang-qin decoction significantly enhances anticancer activity of irinotecan. Chin. J. Nat. Med., 2021, 19(5), 364-375.
[http://dx.doi.org/10.1016/S1875-5364(21)60034-1] [PMID: 33941341]
[51]
Murai, T.; Matsuo, M.; Tanaka, H.; Manabe, Y.; Takaoka, T.; Hachiya, K.; Yamaguchi, T.; Otsuka, S.; Shibamoto, Y. Efficacy of herbal medicine TJ-14 for acute radiation-induced enteritis: A multi-institutional prospective Phase II trial. J. Radiat. Res., 2020, 61(1), 140-145.
[http://dx.doi.org/10.1093/jrr/rrz025] [PMID: 31691810]
[52]
Hu, Z.P.; Yang, X.X.; Chen, X.; Cao, J.; Chan, E.; Duan, W.; Huang, M.; Yu, X.Q.; Wen, J.Y.; Zhou, S.F. A mechanistic study on altered pharmacokinetics of irinotecan by St. John’s wort. Curr. Drug Metab., 2007, 8(2), 157-171.
[http://dx.doi.org/10.2174/138920007779815995] [PMID: 17305494]
[53]
Birdsall, T.C.St. John’s wort and irinotecan-induced diarrhea. Toxicol. Appl. Pharmacol., 2007, 220(1), 108.
[http://dx.doi.org/10.1016/j.taap.2006.12.019] [PMID: 17276473]
[54]
Hu, Z.P.; Yang, X.X.; Chan, S.Y.; Xu, A.L.; Duan, W.; Zhu, Y.Z.; Sheu, F.S.; Boelsterli, U.A.; Chan, E.; Zhang, Q.; Wang, J.C.; Ee, P.L.R.; Koh, H.L.; Huang, M.; Zhou, S.F.St. John’s wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol. Appl. Pharmacol., 2006, 216(2), 225-237.
[http://dx.doi.org/10.1016/j.taap.2006.05.020] [PMID: 17015070]
[55]
Hu, Z.; Yang, X.; Ho, P.C.L.; Chan, E.; Chan, S.Y.; Xu, C.; Li, X.; Zhu, Y.Z.; Duan, W.; Chen, X.; Huang, M.; Yang, H.; Zhou, S.St. John’s wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm. Res., 2005, 22(6), 902-914.
[http://dx.doi.org/10.1007/s11095-005-4585-0] [PMID: 15948034]
[56]
Mathijssen, R.H.J.; Verweij, J.; de Bruijn, P.; Loos, W.J.; Sparreboom, A. Effects of St. John’s wort on irinotecan metabolism. J. Natl. Cancer Inst., 2002, 94(16), 1247-1249.
[http://dx.doi.org/10.1093/jnci/94.16.1247] [PMID: 12189228]
[57]
Endo, M.; Hori, M.; Ozaki, H.; Oikawa, T.; Hanawa, T. Daikenchuto, a traditional Japanese herbal medicine, ameliorates postoperative ileus by anti-inflammatory action through nicotinic acetylcholine receptors. J. Gastroenterol., 2014, 49(6), 1026-1039.
[http://dx.doi.org/10.1007/s00535-013-0854-6] [PMID: 23846546]
[58]
Itoh, T.; Yamakawa, J.; Mai, M.; Yamaguchi, N.; Kanda, T. The effect of the herbal medicine dai-kenchu-to on post-operative ileus. J. Int. Med. Res., 2002, 30(4), 428-432.
[http://dx.doi.org/10.1177/147323000203000410] [PMID: 12235926]
[59]
Satoh, K.; Kase, Y.; Hayakawa, T.; Murata, P.; Ishige, A.; Sasaki, H. Dai-kenchu-to enhances accelerated small intestinal movement. Biol. Pharm. Bull., 2001, 24(10), 1122-1126.
[http://dx.doi.org/10.1248/bpb.24.1122] [PMID: 11642315]
[60]
Yoshikawa, K.; Higashijima, J.; Miyatani, T.; Miyamoto, H.; Miyatani, T. Kampo medicine “Dai-kenchu-to” prevents bacterial transloca-tion in rats. Dig. Dis. Sci., 2008, 58, 1824.
[http://dx.doi.org/10.1007/s10620-008-0281-3] [PMID: 18446437]
[61]
Chikakiyo, M.; Shimada, M.; Nakao, T.; Higashijima, J.; Yoshikawa, K.; Nishioka, M.; Iwata, T.; Kurita, N. Kampo medicine “Dai-kenchu-to” prevents CPT-11-induced small-intestinal injury in rats. Surg. Today, 2012, 42(1), 60-67.
[http://dx.doi.org/10.1007/s00595-011-0014-7] [PMID: 22068671]
[62]
Liu, Z.; Xi, J.; Schröder, S.; Wang, W.; Xie, T.; Wang, Z.; Bao, S.; Fei, J. Chimonanthus nitens var. salicifolius aqueous extract protects against 5-fluorouracil induced gastrointestinal mucositis in a mouse model. Evid. Based Complement. Alternat. Med., 2013, 2013, 1-12.
[http://dx.doi.org/10.1155/2013/789263] [PMID: 24367389]
[63]
Wagh, V.D. Propolis: A wonder bees product and its pharmacological potentials. Adv. Pharmacol. Sci., 2013, 2013, 1-11.
[http://dx.doi.org/10.1155/2013/308249] [PMID: 24382957]
[64]
Benkovic, V.; Horvat Knezevic, A.; Brozovic, G.; Knezevic, F.; Đikic, D.; Bevanda, M.; Basic, I.; Orsolic, N. Enhanced antitumor activity of irinotecan combined with propolis and its polyphenolic compounds on ehrlich ascites tumor in mice. Biomed. Pharmacother., 2007, 61(5), 292-297.
[http://dx.doi.org/10.1016/j.biopha.2007.02.012] [PMID: 17412551]
[65]
Oršolić, N.; Benković, V.; Lisičić, D.; Đikić, D.; Erhardt, J.; Horvat Knežević, A. Protective effects of propolis and related polyphenol-ic/flavonoid compounds against toxicity induced by irinotecan. Med. Oncol., 2010, 27(4), 1346-1358.
[http://dx.doi.org/10.1007/s12032-009-9387-5] [PMID: 20013318]
[66]
Li, T.; Ito, K.; Sumi, S.; Fuwa, T.; Horie, T. Protective effect of aged garlic extract (AGE) on the apoptosis of intestinal epithelial cells caused by methotrexate. Cancer Chemother. Pharmacol., 2009, 63(5), 873-880.
[http://dx.doi.org/10.1007/s00280-008-0809-4] [PMID: 18677483]
[67]
Yüncü, M.; Eralp, A.; Celõk, A. Effect of aged garlic extract against methotrexate-induced damage to the small intestine in rats. Phytother. Res., 2006, 20(6), 504-510.
[http://dx.doi.org/10.1002/ptr.1896] [PMID: 16619342]
[68]
Horie, T.; Li, T.; Ito, K.; Sumi, S.; Fuwa, T. Aged garlic extract protects against methotrexate-induced apoptotic cell injury of IEC-6 cells. J. Nutr., 2006, 136(Suppl. 3), 861S-863S.
[http://dx.doi.org/10.1093/jn/136.3.861S] [PMID: 16484581]
[69]
Knežević, A.H.; Đikić, D.; Lisičić, D.; Kopjar, N.; Oršolić, N.; Karabeg, S.; Benković, V. Synergistic effects of irinotecan and flavonoids on Ehrlich ascites tumour-bearing mice. Basic Clin. Pharmacol. Toxicol., 2011, 109(5), 343-349.
[http://dx.doi.org/10.1111/j.1742-7843.2011.00735.x] [PMID: 21624058]
[70]
Bansal, T.; Awasthi, A.; Jaggi, M.; Khar, R.K.; Talegaonkar, S. Pre-clinical evidence for altered absorption and biliary excretion of iri-notecan (CPT-11) in combination with quercetin: Possible contribution of P-glycoprotein. Life Sci., 2008, 83(7-8), 250-259.
[http://dx.doi.org/10.1016/j.lfs.2008.06.007] [PMID: 18619980]
[71]
Takasuna, K.; Kasai, Y.; Kitano, Y.; Mori, K.; Kobayashi, R.; Hagiwara, T.; Kakihata, K.; Hirohashi, M.; Nomura, M.; Nagai, E.; Ka-mataki, T. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, iri-notecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res., 1995, 86(10), 978-984.
[http://dx.doi.org/10.1111/j.1349-7006.1995.tb03010.x] [PMID: 7493918]
[72]
Takasuna, K.; Hagiwara, T.; Hirohashi, M.; Kato, M.; Nomura, M.; Nagai, E.; Yokoi, T.; Kamataki, T. Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother. Pharmacol., 1998, 42(4), 280-286.
[http://dx.doi.org/10.1007/s002800050818] [PMID: 9744772]
[73]
Walle, T.; Otake, Y.; Brubaker, J.A.; Walle, U.K.; Halushka, P.V. Disposition and metabolism of the flavonoid chrysin in normal volun-teers. Br. J. Clin. Pharmacol., 2001, 51(2), 143-146.
[http://dx.doi.org/10.1111/j.1365-2125.2001.01317.x] [PMID: 11259985]
[74]
Galijatovic, A.; Otake, Y.; Walle, U.K.; Walle, T. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells-potential role in carcinogen bioinactivation. Pharm. Res., 2001, 18(3), 374-379.
[http://dx.doi.org/10.1023/A:1011019417236] [PMID: 11442279]
[75]
Tobin, P.J.; Beale, P.; Noney, L.; Liddell, S.; Rivory, L.P.; Clarke, S. A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemother. Pharmacol., 2006, 57(3), 309-316.
[http://dx.doi.org/10.1007/s00280-005-0053-0] [PMID: 16003560]
[76]
Clinicaltrials.gov xcht for irinotecan induced gut toxicities ( run in study). Available at: https://clinicaltrials.gov/ct2/show/NCT04926545 (accessed January 13)
[77]
Deng, C.; Lou, Y.; Gao, Y.; Deng, B.; Su, F.; Jia, L. Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: Study protocol for a multicenter randomized controlled trial. Trials, 2020, 21(1), 370.
[http://dx.doi.org/10.1186/s13063-020-04275-5] [PMID: 32357899]
[78]
Kummar, S.; Copur, M.S.; Rose, M.; Wadler, S.; Stephenson, J.; O’Rourke, M.; Brenckman, W.; Tilton, R.; Liu, S.H.; Jiang, Z.; Su, T.; Cheng, Y.; Chu, E. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin. Colorectal Cancer, 2011, 10(2), 85-96.
[http://dx.doi.org/10.1016/j.clcc.2011.03.003] [PMID: 21859559]
[79]
Yen, Y.; So, S.; Rose, M.; Saif, M.W.; Chu, E.; Liu, S.H.; Foo, A.; Jiang, Z.; Su, T.; Cheng, Y.C. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res., 2009, 29(10), 4083-4092.
[PMID: 19846955]
[80]
Saif, M.W.; Lansigan, F.; Ruta, S.; Lamb, L.; Mezes, M.; Elligers, K.; Grant, N.; Jiang, Z.L.; Liu, S.H.; Cheng, Y.C. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine, 2010, 17(3-4), 161-169.
[http://dx.doi.org/10.1016/j.phymed.2009.12.016] [PMID: 20092990]
[81]
Xu, H.X.; Huang, X.E.; Li, Y.; Li, C.G.; Tang, J.H. A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac. J. Cancer Prev., 2011, 12(9), 2233-2236.
[PMID: 22296362]
[82]
WANG J. X. X. A clinical study of XELOX chemotherapy combined with Chinese herbal medicines for obstructive colorectal cancer. Int. J. Tradit. Chin. Med., 2016, (6), 523-526.
[83]
Liu, N.; Wu, C.; Jia, R.; Cai, G.; Wang, Y.; Zhou, L.; Ji, Q.; Sui, H.; Zeng, P.; Xiao, H.; Liu, H.; Huo, J.; Feng, Y.; Deng, W.; Li, Q. Tradi-tional chinese medicine combined with chemotherapy and cetuximab or bevacizumab for metastatic colorectal cancer: A randomized, double-blind, placebo-controlled clinical trial. Front. Pharmacol., 2020, 11, 478.
[http://dx.doi.org/10.3389/fphar.2020.00478] [PMID: 32372960]
[84]
Zhang, Y.; Guo, L.L.; Zhao, S.P. Effect of shenqi fuzheng injection combined with chemotherapy in treating colorectal cancer. Zhongguo. Zhong. Xi. Yi. Jie. He. Za. Zhi., 2010, 30(3), 280-282.
[PMID: 20535927]
[85]
Chang, T.K.; Yin, T.C.; Su, W.C.; Tsai, H.L.; Huang, C.W.; Chen, Y.C.; Li, C.C.; Chen, P.J.; Ma, C.J.; Chuang, K.H.; Cheng, T.L.; Wang, J.Y. A pilot study of silymarin as supplementation to reduce toxicities in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. Oncol. Res., 2021, 28(7), 801-809.
[http://dx.doi.org/10.3727/096504021X16218531628569] [PMID: 34030768]
[86]
Matsuda, C.; Munemoto, Y.; Mishima, H.; Nagata, N.; Oshiro, M.; Kataoka, M.; Sakamoto, J.; Aoyama, T.; Morita, S.; Kono, T. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. Cancer Chemother. Pharmacol., 2015, 76(1), 97-103.
[http://dx.doi.org/10.1007/s00280-015-2767-y] [PMID: 25983022]
[87]
Mori, K.; Kondo, T.; Kamiyama, Y.; Kano, Y.; Tominaga, K. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol., 2003, 51(5), 403-406.
[http://dx.doi.org/10.1007/s00280-003-0585-0] [PMID: 12687289]
[88]
Yamazaki, K.; Ariyoshi, N.; Miyauchi, H.; Ohira, G.; Kaneya, N.; Yamamoto, K.; Arai, K.; Yamazaki, S.; Matsubara, H.; Suzuki, T.; Ishii, I. A randomized controlled, open‐label early phase II trial comparing incidence of FOLFIRI.3‐induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer. J. Clin. Pharm. Ther., 2019, 44(6), 946-951.
[http://dx.doi.org/10.1111/jcpt.13020] [PMID: 31407827]
[89]
Hoshi, N.; Kofunato, Y.; Yashima, R.; Shimura, T.; Takenoshita, S. Treating side effects of FOLFIRINOX--A study of the effect of hange-shashin-to on preventing diarrhea. Gan To Kagaku Ryoho, 2015, 42(12), 2364-2366.
[PMID: 26805365]
[90]
Lu, H.; Qin, J.; Han, N.; Xie, F.; Gong, L.; Li, C. Banxia xiexin decoction is effective to prevent and control irinotecan-induced delayed diarrhea in recurrent small cell lung cancer. Integr. Cancer Ther., 2018, 17(4), 1109-1114.
[http://dx.doi.org/10.1177/1534735418801532] [PMID: 30229683]
[91]
Oki, E.; Emi, Y.; Kojima, H.; Higashijima, J.; Kato, T.; Miyake, Y.; Kon, M.; Ogata, Y.; Takahashi, K.; Ishida, H.; Saeki, H.; Sakaguchi, Y.; Yamanaka, T.; Kono, T.; Tomita, N.; Baba, H.; Shirabe, K.; Kakeji, Y.; Maehara, Y. Preventive effect of Goshajinkigan on peripheral neu-rotoxicity of FOLFOX therapy (GENIUS trial): A placebo-controlled, double-blind, randomized phase III study. Int. J. Clin. Oncol., 2015, 20(4), 767-775.
[http://dx.doi.org/10.1007/s10147-015-0784-9] [PMID: 25627820]
[92]
Kono, T.; Hata, T.; Morita, S.; Munemoto, Y.; Matsui, T.; Kojima, H.; Takemoto, H.; Fukunaga, M.; Nagata, N.; Shimada, M.; Sakamoto, J.; Mishima, H. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): A phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother. Pharmacol., 2013, 72(6), 1283-1290.
[http://dx.doi.org/10.1007/s00280-013-2306-7] [PMID: 24121454]
[93]
Chen, J.X.; Shen, X.H. Effects of qisheng mixture on chemotherapy induced myelosuppression in patients with colorectal cancer. Zhongguo. Zhong. Xi. Yi. Jie. He. Za. Zhi., 2012, 32(9), 1161-1165.
[PMID: 23185750]
[94]
Wallace, B.D.; Wang, H.; Lane, K.T.; Scott, J.E.; Orans, J.; Koo, J.S.; Venkatesh, M.; Jobin, C.; Yeh, L.A.; Mani, S.; Redinbo, M.R. Allevi-ating cancer drug toxicity by inhibiting a bacterial enzyme. Sci., 2010, 330(6005), 831-835.
[http://dx.doi.org/10.1126/science.1191175] [PMID: 21051639]
[95]
Takatori, E.; Shoji, T.; Miura, Y.; Takeuchi, S.; Yoshizaki, A.; Sugiyama, T. Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin thera-py. J. Obstet. Gynaecol. Res., 2013, 39(8), 1354-1358.
[http://dx.doi.org/10.1111/jog.12062] [PMID: 23800356]
[96]
Wang, P.; Jia, Y.; Wu, R.; Chen, Z.; Yan, R. Human gut bacterial β-glucuronidase inhibition: An emerging approach to manage medication therapy. Biochem. Pharmacol., 2021, 190, 114566.
[http://dx.doi.org/10.1016/j.bcp.2021.114566] [PMID: 33865833]
[97]
Takasuna, K.; Hagiwara, T.; Watanabe, K.; Onose, S.; Yoshida, S.; Kumazawa, E.; Nagai, E.; Kamataki, T. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother. Pharmacol., 2006, 58(4), 494-503.
[http://dx.doi.org/10.1007/s00280-006-0187-8] [PMID: 16437251]
[98]
Takasuna, K.; Hagiwara, T.; Hirohashi, M.; Kato, M.; Nomura, M.; Nagai, E.; Yokoi, T.; Kamataki, T. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res., 1996, 56(16), 3752-3757.
[PMID: 8706020]
[99]
Sun, R.; Basu, S.; Zeng, M.; Sunsong, R.; Li, L.; Ghose, R.; Wang, W.; Liu, Z.; Hu, M.; Gao, S. Xiao-Chai-Hu-Tang (XCHT) Intervening irinotecan’s disposition: The potential of XCHT in Alleviating irinotecan-induced diarrhea. Curr. Cancer Drug Targets, 2019, 19(7), 551-560.
[http://dx.doi.org/10.2174/1568009618666181029153255] [PMID: 31509102]
[100]
Sun, R.; Zeng, M.; Du, T.; Li, L.; Yang, G.; Hu, M.; Gao, S. Simultaneous determinations of 17 marker compounds in Xiao–Chai–Hu–Tang by LC–MS/MS: Application to its pharmacokinetic studies in mice. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2015, 1003, 12-21.
[http://dx.doi.org/10.1016/j.jchromb.2015.09.004] [PMID: 26397748]
[101]
Melo, M.L.P.; Brito, G.A.C.; Soares, R.C.; Carvalho, S.B.L.M.; Silva, J.V.; Soares, P.M.G.; Vale, M.L.; Souza, M.H.L.P.; Cunha, F.Q.; Ribeiro, R.A. Role of cytokines (TNF-α, IL-1β and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: Effect of pentoxifylline and thalidomide. Cancer Chemother. Pharmacol., 2008, 61(5), 775-784.
[http://dx.doi.org/10.1007/s00280-007-0534-4] [PMID: 17624531]
[102]
Kase, Y.; Hayakawa, T.; Togashi, Y.; Kamataki, T. Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats. Jpn. J. Pharmacol., 1997, 75(4), 399-405.
[http://dx.doi.org/10.1254/jjp.75.399] [PMID: 9469646]
[103]
Sakai, H.; Diener, M.; Gartmann, V.; Takeguchi, N. Eicosanoid-mediated Cl? secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon. Naunyn Schmiedebergs Arch. Pharmacol., 1995, 351(3), 309-314.
[http://dx.doi.org/10.1007/BF00233252] [PMID: 7609786]
[104]
Lee, C.S.; Ryan, E.J.; Doherty, G.A. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation. WJG, 2014, 20(14), 3751-3761.
[http://dx.doi.org/10.3748/wjg.v20.i14.3751] [PMID: 24744571]
[105]
Lam, W.; Bussom, S.; Guan, F.; Jiang, Z.; Zhang, W.; Gullen, E.A.; Liu, S.H.; Cheng, Y.C. The four-herb Chinese medicine PHY906 re-duces chemotherapy-induced gastrointestinal toxicity. Sci. Transl. Med., 2010, 2(45), 45ra59.
[http://dx.doi.org/10.1126/scitranslmed.3001270] [PMID: 20720216]
[106]
Wang, E.; Bussom, S.; Chen, J.; Quinn, C.; Bedognetti, D.; Lam, W.; Guan, F.; Jiang, Z.; Mark, Y.; Zhao, Y.; Stroncek, D.F.; White, J.; Marincola, F.M.; Cheng, Y.C. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tu-mor microenvironment. BMC Med. Genomics, 2011, 4(1), 38.
[http://dx.doi.org/10.1186/1755-8794-4-38] [PMID: 21569348]
[107]
Kong, S.; Zhang, Y.H.; Zhang, W. Regulation of intestinal epithelial cells properties and functions by amino acids. BioMed Res. Int., 2018, 2018, 1-10.
[http://dx.doi.org/10.1155/2018/2819154] [PMID: 29854738]
[108]
Katagiri, F.; Inoue, S.; Sato, Y.; Itoh, H.; Takeyama, M. Lansoprazole raises somatostatin, calcitonin gene-related peptide, and substance P levels in healthy human plasma. J. Health Sci., 2005, 51(3), 294-299.
[http://dx.doi.org/10.1248/jhs.51.294]
[109]
Schmidt, P.T.; Holst, J.J. Tachykinins in regulation of gastric motility and secretion. Cell. Mol. Life Sci., 2000, 57(4), 579-588.
[http://dx.doi.org/10.1007/PL00000720] [PMID: 11130458]
[110]
Naito, T.; Itoh, H.; Yasunaga, F.; Takeyama, M. Hange-shashin-to raises levels of somatostatin, motilin, and gastrin in the plasma of healthy subjects. Biol. Pharm. Bull., 2002, 25(3), 327-331.
[http://dx.doi.org/10.1248/bpb.25.327] [PMID: 11913527]
[111]
Naito, T.; Itoh, H.; Takeyama, M. Comparison of the effects of hange-shashin-to and rikkunshi-to on human plasma calcitonin gene-related peptide and substance P levels. Biol. Pharm. Bull., 2003, 26(8), 1104-1107.
[http://dx.doi.org/10.1248/bpb.26.1104] [PMID: 12913259]
[112]
Fata, F.; Ron, I.G.; Kemeny, N.; O’Reilly, E.; Klimstra, D.; Kelsen, D.P. 5-Fluorouracil-induced small bowel toxicity in patients with colo-rectal carcinoma. Cancer, 1999, 86(7), 1129-1134.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19991001)86:7<1129:AID-CNCR5>3.0.CO;2-4] [PMID: 10506695]
[113]
Ribeiro, R.A.; Wanderley, C.W.S.; Wong, D.V.T.; Mota, J.M.S.C.; Leite, C.A.V.G.; Souza, M.H.L.P.; Cunha, F.Q.; Lima-Júnior, R.C.P. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: Insights into pathogenesis and therapeutic perspectives. Cancer Chemother. Pharmacol., 2016, 78(5), 881-893.
[http://dx.doi.org/10.1007/s00280-016-3139-y] [PMID: 27590709]
[114]
Zhang, F.; Chen, H.; Zhang, R.; Liu, Y.; Kong, N.; Guo, Y.; Xu, M. 5-Fluorouracil induced dysregulation of the microbiome-gut-brain axis manifesting as depressive like behaviors in rats. Biochim. Biophys. Acta Mol. Basis Dis., 2020, 1866(10), 165884.
[http://dx.doi.org/10.1016/j.bbadis.2020.165884] [PMID: 32574836]
[115]
Xiong, Y.; Shang, B.; Xu, S.; Zhao, R.; Gou, H.; Wang, C. Protective effect of Bu-zhong-yi-qi decoction, the water extract of Chinese tradi-tional herbal medicine, on 5-fluorouracil-induced renal injury in mice. Ren. Fail., 2016, 38(8), 1240-1248.
[http://dx.doi.org/10.1080/0886022X.2016.1209380] [PMID: 27435211]
[116]
Liu, J.H.; Hsieh, C.H.; Liu, C.Y.; Chang, C.W.; Chen, Y.J.; Tsai, T.H. Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice. J. Ethnopharmacol., 2021, 271, 113912.
[http://dx.doi.org/10.1016/j.jep.2021.113912] [PMID: 33567307]
[117]
Deng, C.; Deng, B.; Jia, L.; Tan, H.; Zhang, P.; Liu, S.; Zhang, Y.; Song, A.; Pan, L. Preventive effects of a chinese herbal formula, shengjiang xiexin decoction, on irinotecan-induced delayed-onset diarrhea in rats. Evid. Based Complement. Alternat. Med., 2017, 2017, 1-10.
[http://dx.doi.org/10.1155/2017/7350251] [PMID: 28167974]
[118]
Clinicaltrials.gov clinical study o n prevention and treatment of pyrotinib associated diarrhea with traditional chinese medicine. Available at: https://ClinicalTrials.gov/show/NCT04988165 (accessed January 13, 2023).
[119]
Fang, Z.; Zhang, M.; Yi, Z.; Wen, C.; Qian, M.; Shi, T. Replacements of rare herbs and simplifications of traditional chinese medicine for-mulae based on attribute similarities and pathway enrichment analysis. Evid. Based Complement. Alternat. Med., 2013, 2013, 1-9.
[http://dx.doi.org/10.1155/2013/136732] [PMID: 23533462]
[120]
Sakata, Y.; Suzuki, H.; Kamataki, T. Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hy-drochloride (CPT-11). Gan To Kagaku Ryoho, 1994, 21(8), 1241-1244.
[PMID: 8031168]
[121]
Borse, S.P.; Singh, D.P.; Nivsarkar, M. Understanding the relevance of herb–drug interaction studies with special focus on interplays: A prerequisite for integrative medicine. Porto Biomed. J., 2019, 4(2), e15.
[http://dx.doi.org/10.1016/j.pbj.0000000000000015] [PMID: 31595257]
[122]
Fasinu, P.S.; Bouic, P.J.; Rosenkranz, B. An overview of the evidence and mechanisms of herb-drug interactions. Front. Pharmacol., 2012, 3, 69.
[http://dx.doi.org/10.3389/fphar.2012.00069] [PMID: 22557968]
[123]
Hu, X.Q.; Sun, Y.; Lau, E.; Zhao, M.; Su, S.B. Advances in synergistic combinations of chinese herbal medicine for the treatment of can-cer. Curr. Cancer Drug Targ., 2016, 16(4), 346-356.
[http://dx.doi.org/10.2174/1568009616666151207105851] [PMID: 26638885]
[124]
Zhang, X.S.; Zhao, Z.Q.; Qin, Z.S.; Wu, K.; Xia, T.F.; Pang, L.Q. Herb-drug interaction between irinotecan and psoralidin-containing herbs. Eur. J. Drug Metab. Pharmacokinet., 2015, 40(4), 481-484.
[http://dx.doi.org/10.1007/s13318-014-0223-8] [PMID: 25216634]
[125]
Gbolahan, O.B.; O’Neil, B.H.; McRee, A.J.; Sanoff, H.K.; Fallon, J.K.; Smith, P.C.; Ivanova, A.; Moore, D.T.; Dumond, J.; Asher, G.N. A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors. Clin. Transl. Sci., 2022, 15(5), 1304-1315.
[http://dx.doi.org/10.1111/cts.13250] [PMID: 35157783]
[126]
Clinical pharmacology and biopharmaceutics review(s). Center for Drug Evaluation and Res. Ed;, 2012.
[127]
Shiozawa, T.; Tadokoro, J.; Fujiki, T.; Fujino, K.; Kakihata, K.; Masatani, S.; Morita, S.; Gemma, A.; Boku, N. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: A postmarketing survey. Jpn. J. Clin. Oncol., 2013, 43(5), 483-491.
[http://dx.doi.org/10.1093/jjco/hyt040] [PMID: 23536639]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy